Abstract
Hepatic fat accumulation is the hallmark of non-alcoholic fatty liver disease (NAFLD). Our aim was to determine the plasma levels of oxylipins, free polyunsaturated fatty acids (PUFA) and markers of lipid peroxidation in patients with NAFLD in progressive stages of the pathology. Ninety 40–60-year-old adults diagnosed with metabolic syndrome were distributed in without, mild, moderate or severe NAFLD stages. The free PUFA and oxylipin plasma levels were determined by the UHPLC–MS/MS system. The plasma levels of oxylipins produced by cyclooxygenases, lipoxygenases and cytochrome P450, such as prostaglandin 2α (PGF2α), lipoxinB4 and maresin-1, were higher in severe NAFLD patients, pointing to the coexistence of both inflammation and resolution processes. The plasma levels of the saturated oxylipins 16-hydroxyl-palmitate and 3-hydroxyl-myristate were also higher in the severe NAFLD patients, suggesting a dysregulation of oxidation of fatty acids. The plasma 12-hydroxyl-estearate (12HEST) levels in severe NAFLD were higher than in the other stages, indicating that the hydroxylation of saturated fatty acid produced by reactive oxygen species is more present in this severe stage of NAFLD. The plasma levels of 12HEST and PGF2α are potential candidate biomarkers for diagnosing NAFLD vs. non-NAFLD. In conclusion, the NAFLD progression can be monitored by measuring the plasma levels of free PUFA and oxylipins characterizing the different NAFLD stages or the absence of this disease in metabolic syndrome patients.
Funding Information
  • Fundació la Marató TV3 (201630.10, CIBEROBN CB12/03/30038, CIBER OBN18PI03, PEJ2018-002452-A, JUNIOR19-05)
  • Instituto de Salud Carlos III through the Fondo de Investigación para la Salud (201630.10, CIBEROBN CB12/03/30038, CIBER OBN18PI03, PEJ2018-002452-A, JUNIOR19-05)
  • European Regional Development Fund. C.R. was funded by the Youth Guarantee program of the Ministry of Science, Innovation and Universities of the Government of Spain and European Social Funds (201630.10, CIBEROBN CB12/03/30038, CIBER OBN18PI03, PEJ2018-002452-A, JUNIOR19-05)
  • Health Research Institute of Balearic Islands (IdISBa) (201630.10, CIBEROBN CB12/03/30038, CIBER OBN18PI03, PEJ2018-002452-A, JUNIOR19-05)

This publication has 66 references indexed in Scilit: